ArticleAAPS PharmSciTech2026
Levofloxacin Inhalation Solution: Superior Efficacy and Minimized Hepatotoxicity Against Chronic Pseudomonas Aeruginosa-Induced Pulmonary Infection.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Pseudomonas aeruginosa (PA)-induced pulmonary infection poses a severe global health threat due to limited therapeutic efficacy of conventional systemic administration and rising drug resistance. Inhalation therapy offers targeted pulmonary drug delivery but is hindered by suboptimal formulations and inefficient nebulizers. Herein, we developed a novel levofloxacin inhalation solution (LIS) and a custom-engineered vibrating-mesh nebulizer (PJ-102) as a synergistic drug-device combination for the treatment of chronic pulmonary infection. LIS exhibited excellent aerosolization performance with a 1.81-fold fine particle fraction of that of commercial jet nebulizer. And the superiority in treating chronic pulmonary infection was also proved by in vivo experiments. Additionally, LIS avoided the hepatotoxicity associated with systemic levofloxacin exposure, as evidenced by stable liver enzyme levels and normal hepatic pathology. This established LIS offered a promising therapeutic candidate for refractory PA-induced pulmonary infections and a valuable framework for advanced antimicrobial inhalation therapy development.
Indexed as
Identifiers
41840258What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.